Advertisement
The HyperQ(TM) is cutting-edge technology implemented in an innovativestress-test system, offering highly reliable, low-cost and risk free cardiacmonitoring for broad populations and allows, for the first time, effectiveand accurate testing for Ischemic heart disease patients.
Advertisement
The HyperQ(TM) system received FDA clearance (510K), as well as theEuropean CE marking. To date, more than 3500 patients in Israel, Europe andthe US have been examined by HyperQ(TM) Stress Systems in controlled clinicalstudies, pilot programs and routine testing in the setting of private officesand hospital clinics. The results have demonstrated the system's highefficiency and unmatched accuracy in the diagnosis of IHD.
The company has entered the clinical and commercial phase, during whichthe HyperQ(TM) Stress System will be integrated in inpatient settings,outpatient cardiology departments, private doctor offices and major researchcenters.
Further applications on the company's scope, based on the same coretechnology, include bedside monitors for ischemic events; devices for cardiachome-care and telemedicine; periodic check-up systems, and the implementationof the HyperQ(TM) technology in implantable cardiac devices such aspacemakers and defibrillators.
Dr. Amir Beker, CEO of BSP says, "BSP's HyperQ(TM) technology is arevolutionary solution to today's most fatal pathology. The HyperQ(TM) StressSystem is a non-invasive solution that will improve the standard of care forcardiac patients and at the same time will help reduce unnecessary costly andpotentially harmful procedures. The HyperQ(TM) Stress System thus addressesdire needs of private and national healthcare systems to balance the immensecosts of cardiac diagnosis and monitoring, while decreasing the risk offurther, often invasive, tests for cardiac patients".
About BSP
BSP is dedicated to providing novel, risk free and highly reliablesolutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP wasfounded in 2000 by Dr. Amir Beker and Mr. Ariel Landau and has completed asuccessful IPO in mid-2006 and its shares are traded on the Tel Aviv StockExchange.
Contact: Dr. Amir Beker, +972-3-6474840, http://www.bspmedical.com
SOURCE BSP - Biological Signal Processing Ltd
